Xenon Pharmaceuticals Inc. Common Shares XENE
i
Market datapartial · fetched 2026-11-14T02:11:17.053Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T23:32:55.580379805Z
FundamentalsAlpha Vantage · unavailable
Xenon Pharmaceuticals Inc. Common Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 44.89 | 84.8% | 12.4% | 34.37 | 161.4% | 17.6% |
| 25Δ | 44.03 | 82.2% | 10.6% | 37.78 | 78.2% | 8.2% |
| 30Δ | 43.18 | 79.6% | 8.9% | 38.36 | 79.3% | 7.4% |
| 35Δ | 42.38 | 77.0% | 7.3% | 38.94 | 80.4% | 6.5% |
| 40Δ | 41.83 | 74.3% | 6.3% | 39.52 | 81.5% | 5.7% |
| 45Δ | 41.27 | 71.7% | 5.4% | 40.08 | 81.6% | 4.9% |
| 50Δ | 40.71 | 69.0% | 4.4% | 40.54 | 77.5% | 4.2% |
| 55Δ | 40.15 | 66.3% | 3.4% | 41.00 | 73.3% | 3.5% |
| 60Δ | 39.41 | 75.3% | 3.1% | 41.46 | 69.2% | 2.9% |
| 65Δ | 38.61 | 88.8% | 3.0% | 41.91 | 65.0% | 2.2% |
| 70Δ | 37.80 | 102.2% | 2.9% | 42.37 | 60.9% | 1.5% |
| 75Δ | 37.01 | 104.7% | 2.5% | |||
| 80Δ | 36.23 | 100.6% | 1.9% | |||
20Δ
- Pseudo strike
- 44.89
- IV
- 84.8%
- B/E move
- 12.4%
- Pseudo strike
- 34.37
- IV
- 161.4%
- B/E move
- 17.6%
25Δ
- Pseudo strike
- 44.03
- IV
- 82.2%
- B/E move
- 10.6%
- Pseudo strike
- 37.78
- IV
- 78.2%
- B/E move
- 8.2%
30Δ
- Pseudo strike
- 43.18
- IV
- 79.6%
- B/E move
- 8.9%
- Pseudo strike
- 38.36
- IV
- 79.3%
- B/E move
- 7.4%
35Δ
- Pseudo strike
- 42.38
- IV
- 77.0%
- B/E move
- 7.3%
- Pseudo strike
- 38.94
- IV
- 80.4%
- B/E move
- 6.5%
40Δ
- Pseudo strike
- 41.83
- IV
- 74.3%
- B/E move
- 6.3%
- Pseudo strike
- 39.52
- IV
- 81.5%
- B/E move
- 5.7%
45Δ
- Pseudo strike
- 41.27
- IV
- 71.7%
- B/E move
- 5.4%
- Pseudo strike
- 40.08
- IV
- 81.6%
- B/E move
- 4.9%
50Δ
- Pseudo strike
- 40.71
- IV
- 69.0%
- B/E move
- 4.4%
- Pseudo strike
- 40.54
- IV
- 77.5%
- B/E move
- 4.2%
55Δ
- Pseudo strike
- 40.15
- IV
- 66.3%
- B/E move
- 3.4%
- Pseudo strike
- 41.00
- IV
- 73.3%
- B/E move
- 3.5%
60Δ
- Pseudo strike
- 39.41
- IV
- 75.3%
- B/E move
- 3.1%
- Pseudo strike
- 41.46
- IV
- 69.2%
- B/E move
- 2.9%
65Δ
- Pseudo strike
- 38.61
- IV
- 88.8%
- B/E move
- 3.0%
- Pseudo strike
- 41.91
- IV
- 65.0%
- B/E move
- 2.2%
70Δ
- Pseudo strike
- 37.80
- IV
- 102.2%
- B/E move
- 2.9%
- Pseudo strike
- 42.37
- IV
- 60.9%
- B/E move
- 1.5%
75Δ
- Pseudo strike
- 37.01
- IV
- 104.7%
- B/E move
- 2.5%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 36.23
- IV
- 100.6%
- B/E move
- 1.9%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 50.76% | |
| 50.40% | |
| 50.51% | |
| 51.84% | |
| 54.31% | |
| 55.67% | |
| 56.92% | |
| 53.43% | |
| 48.74% | |
| 57.76% |
Biotechnology
XFOR
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of new therapies for the treatment of back…
More →XNCR
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed to treat cancer patients…
More →ZBIO
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. The company is…
More →ZLAB
Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops and markets therapies to treat cancer, autoimmune and infectious diseases in China. The company is…
More →ZNTL
Description unavailable
More →ZURA
Description unavailable
More →